Editorial: The challenge of dengue vaccine development and introduction

J. Deen

DOI: https://doi.org/10.1046/j.1365-3156.2003.01159.x

2004-01-01

Tropical Medicine & International Health

Abstract:The Bill and Melinda Gates Foundation recently awarded a 55 million dollar grant to the paediatric dengue vaccine initiative (PDVI). The grant is very much needed to accelerate the development and introduction of a dengue vaccine. Dengue, especially its more sinister forms dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS), is a frightening disease. This mosquito-borne illness strikes suddenly, causing ‘break-bone’ fever with the risk of capillary leakage, bleeding and death. An estimated 50 million dengue infections occur annually, including 500 000 cases of DHF/DSS, with 24 000 deaths mostly in children. The burden is greatest in tropical Asia where dengue is a leading cause of paediatric hospitalization. Before 1970, only nine countries were reporting DHF epidemics, a number which has since increased more than fourfold (World Health Organization 2000). In recent years, several Latin American countries have been experiencing dengue outbreaks with serious consequences. The battle against dengue has focused on improving recognition and case management. The need for differentiation from other causes of fever and the lack of clinical predictors of severe disease complicate diagnosis. During the dengue season, particularly during outbreaks that occur every 3–4 years, health care facilities are inundated by fearful parents bringing in febrile children for evaluation and admission. Due to the progressive nature of the illness, repeated assessments over a period of about 3–7 days of fever are necessary. Lenient hospitalization policies allow close observation and improve outcome but use up precious resources. The illness is particularly cruel in that complications usually occur just as the patient starts to defervesce. The cornerstone of management is closely monitored intravenous fluid replacement. Where skilled staff and facilities are available, the case-fatality rate has been brought down to <1% but remains as high as 10–30% in poor countries or during outbreaks. The occurrence of repeat dengue episodes aggravates the situation. The virus has four serotypes and infection with one provides life-long immunity against that same but not the other serotypes. Not only do repeated episodes occur but the risk of severe illness is increased at least 15-fold during secondary compared with primary infections (Halstead 1980). Various mechanisms have been suggested to explain this phenomenon. Enhancement of virus replication in mononuclear cells by antibodies from a previous heterologous dengue virus infection has been demonstrated (Halstead 1988). Most recently, investigators have suggested that increased T-cell activation and apoptosis may contribute to the systemic disturbances leading to DHF (Mongkolsapaya et al. 2003). The impact of dengue is not only in terms of suffering from disease and death. Dengue imposes an economic burden including private expenditures for medical care and time taken from work to look after ill family members; government costs for provision of treatment and control activities; and lost revenue from tourism and industry. Currently, there is no sustainable preventive approach against dengue. Community-based mosquito control projects have succeeded on a small scale but national programmes have only been effective under strong central government supervision. Vector control has not provided wide-spread and long-lasting results. Vaccination offers greater hope as an effective and sustainable strategy (Jacobs 2000). Several multivalent dengue vaccines are in various stages of development but none of them is close to licensure (Halstead & Deen 2002). A live attenuated vaccine is thought to be the most promising design. Live attenuated viral vaccines actively replicate in the host resulting in an array of wild virus-like antigens, which could potentially provoke a response similar to natural immunity. Intracellular replication of the virus elicits strong cytotoxic T-cell responses. Long-term memory T-cells and immunity are exceptionally durable and complete immunization may be achieved with few doses (Monath et al. 2002). Live attenuated tetravalent dengue vaccines are being developed Tropical Medicine and International Health